TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy

BackgroundConsiderable variability in mortality risk exists among patients with ST-elevation myocardial infarction (STEMI). Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice. Methods and ResultsWe developed and evaluated a convenient bedside clinical risk score for predicting 30-day mortality at presentation of fibrinolytic-eligible patients with STEMI. The Thrombolysis in Myocardial Infarction ( TIMI) risk score for STEMI was created as the simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis in the Intravenous nPA for Treatment of Infarcting Myocardium Early II trial (n=14 114). Mean 30-day mortality was 6.7%. Ten baseline variables, accounting for 97% of the predictive capacity of the multivariate model, constituted the TIMI risk score. The risk score showed a >40-fold graded increase in mortality, with scores ranging from 0 to >8 (P <0.0001); mortality was <1% among patients with a score of 0. The prognostic discriminatory capacity of the TIMI risk score was comparable to the full multivariable model (c statistic 0.779 versus 0.784). The prognostic performance of the risk score was stable over multiple time points (1 to 365 days). External validation in the TIMI 9 trial showed similar prognostic capacity (c statistic 0.746). ConclusionsThe TIMI risk score for STEMI captures the majority of prognostic information offered by a full logistic regression model but is more readily used at the bedside. This risk assessment tool is likely to be clinically useful in the triage and management of fibrinolytic-eligible patients with STEMI.

[1]  P. Brandt,et al.  A new coronary prognostic index. , 1969, American heart journal.

[2]  G. Sanz,et al.  Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. , 1982, The New England journal of medicine.

[3]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[4]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.

[5]  A. Albert,et al.  Short‐term risk stratification at admission based on simple clinical data in acute myocardial infarction , 1989, The American journal of cardiology.

[6]  D Draper,et al.  Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. , 1988, JAMA.

[7]  Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. , 1988 .

[8]  E. Braunwald,et al.  Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. , 1990, Journal of the American College of Cardiology.

[9]  W. O’Neill,et al.  Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. , 1991, Annals of internal medicine.

[10]  P. Kudenchuk,et al.  Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.

[11]  E. Negri,et al.  Determinants of 6‐Month Mortality in Survivors of Myocardial Infarction After Thrombolysis Results of the GISSI‐2 Data Base , 1993, Circulation.

[12]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[13]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[14]  Fibrinolytic Therapy Trialists' Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.

[15]  Fibrinolytictherapytrialistsf Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[16]  E. Antman Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[17]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[18]  U Ludwigs,et al.  Acute Physiology and Chronic Health Evaluation II scoring system in acute myocardial infarction: a prospective validation study. , 1995, Critical care medicine.

[19]  E. Antman Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[20]  J. Rouleau,et al.  Myocardial infarction patients in the 1990s--their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. , 1996, Journal of the American College of Cardiology.

[21]  B. McNeil,et al.  Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. , 1996, JAMA.

[22]  C. Naylor,et al.  Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. , 1996, Journal of the American College of Cardiology.

[23]  R. Califf,et al.  Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. , 1996, Journal of the American College of Cardiology.

[24]  E. Topol Textbook of Cardiovascular Medicine , 1997 .

[25]  A. Rebuzzi,et al.  Need for a composite risk stratification of patients with unstable coronary syndromes tailored to clinical practice. , 1997, Circulation.

[26]  J. Gore,et al.  Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. , 1998, American heart journal.

[27]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[28]  D. Jacobs,et al.  PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. , 1999, Circulation.

[29]  H. Krumholz,et al.  Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. , 1999, Circulation.

[30]  E. Antman,et al.  The length of the hospital stay after myocardial infarction. , 2000, The New England journal of medicine.